These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36662612)

  • 41. Microplastic-mediated new mechanism of liver damage: From the perspective of the gut-liver axis.
    Wang X; Deng K; Zhang P; Chen Q; Magnuson JT; Qiu W; Zhou Y
    Sci Total Environ; 2024 Apr; 919():170962. PubMed ID: 38360312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
    Sun MF; Shen YQ
    Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The shaping of gut immunity in cirrhosis.
    Muñoz L; Caparrós E; Albillos A; Francés R
    Front Immunol; 2023; 14():1139554. PubMed ID: 37122743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity.
    Wei YX; Zheng KY; Wang YG
    World J Gastroenterol; 2021 Sep; 27(33):5555-5565. PubMed ID: 34588751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
    Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut barrier disruption and chronic disease.
    Martel J; Chang SH; Ko YF; Hwang TL; Young JD; Ojcius DM
    Trends Endocrinol Metab; 2022 Apr; 33(4):247-265. PubMed ID: 35151560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gut microbiota changes and chronic hepatitis C virus infection.
    Preveden T; Scarpellini E; Milić N; Luzza F; Abenavoli L
    Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):813-819. PubMed ID: 28621554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dysbiosis of Gut Microbiota and Intestinal Barrier Dysfunction in Pigs with Pulmonary Inflammation Induced by Mycoplasma hyorhinis Infection.
    Zhang Y; Gan Y; Wang J; Feng Z; Zhong Z; Bao H; Xiong Q; Wang R
    mSystems; 2022 Aug; 7(4):e0028222. PubMed ID: 35699454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
    Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
    Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal Barrier in Human Health and Disease.
    Di Tommaso N; Gasbarrini A; Ponziani FR
    Int J Environ Res Public Health; 2021 Dec; 18(23):. PubMed ID: 34886561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Citrus flavonoids and the intestinal barrier: Interactions and effects.
    Wang M; Zhao H; Wen X; Ho CT; Li S
    Compr Rev Food Sci Food Saf; 2021 Jan; 20(1):225-251. PubMed ID: 33443802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut microbiota mediated molecular events and therapy in liver diseases.
    Qi X; Yang M; Stenberg J; Dey R; Fogwe L; Alam MS; Kimchi ET; Staveley-O'Carroll KF; Li G
    World J Gastroenterol; 2020 Dec; 26(48):7603-7618. PubMed ID: 33505139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.
    Shamoon M; Martin NM; O'Brien CL
    Pharmacol Res; 2019 Oct; 148():104344. PubMed ID: 31400403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pivotal Role of Intestinal Microbiota and Intraluminal Metabolites for the Maintenance of Gut-Bone Physiology.
    Grüner N; Ortlepp AL; Mattner J
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.